Assessment of Immunological Outcome Among HIV Infected Patients on First Line Highly Active Antiretroviral Therapy (HAART) in Shashamane Referal Hospital, West Arsi, Oromia Region, Ethiopia

Background: Antiretroviral Therapy (ART) is the cornerstone of management for RVI (Retroviral infected) patients as it restores the immune cells and thereby reducing morbidity and mortality. Understanding the biological and clinical effects of the ARTs is so crucial because a low CD4 count will advance the condition by increasing opportunistic infections.

Objectives: To assess the immunological outcome among RVI patients on HAART in Shashemane referral hospital.

Methods: Retrospective cross sectional study design was used to collect data from the records of HIV/AIDS patients on first line HAART from 2003-2008 E.C in Shashemane referral hospital.Simple random sampling technique was used. Data collection was carried out from March to April in 2017.

Results: A total of 201 RVI patients who were on ART fulfill the inclusion criteria and were included in the study. Out of them 62.2% (N=125) and 37.8% (N=76) were female and male respectively. The mean CD4 count for the regimen TDF+3TC+EFV increase from baseline 228.26 cells/mm³ (SD=132.7) to 547 cells/mm³ (SD=245.7). In similar manner, the mean CD4 count for the regimen ZDV+3TC+EFV increase from baseline 244.86 cells/mm³ (SD=133.9) to 542.7 cells/mm³ (SD=270.7).

Conclusion: The mean CD4 count for those patients who were on first line HAART increases regardless of the regimens.

Author(s): Gemechu Gelana and Tasissa Ayela

Abstract | Full-Text | PDF

Share This Article